AKT1 and neoplasm: As the PI3K/AKT/MTOR pathway is essential for hepatic gluconeogenesis (5), everolimus may counteract hypoglycemia independent of its anti-tumor effect by enhancing the expression of liver gluconeogenic enzymes and nuclear recruitment of gluconeogenic transcriptional regulators (Fig. 2).